IceCure Medical Launches $10 Million Rights Offering

Icecure Medical ( (ICCM) ) has shared an update.

On June 25, 2025, IceCure Medical announced a rights offering to raise up to $10 million, allowing shareholders to purchase additional units of the company’s stock. The offering, which includes participation from its largest shareholder, Epoch Partner Investments Limited, aims to repay a bridge loan and support corporate and working capital needs. The subscription rights expire on July 28, 2025, and the company has engaged Maxim Group LLC as the dealer-manager for this offering.

The most recent analyst rating on (ICCM) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.

Spark’s Take on ICCM Stock

According to Spark, TipRanks’ AI Analyst, ICCM is a Neutral.

The overall score reflects significant financial challenges, with persistent losses and cash flow issues being the most significant factors. Technical indicators and valuation metrics further point to a cautious outlook. While some positive developments exist, such as FDA engagement and regional sales growth, they are overshadowed by ongoing financial difficulties.

To see Spark’s full report on ICCM stock, click here.

More about Icecure Medical

IceCure Medical, listed on Nasdaq as ICCM, specializes in developing and marketing cryoablation therapy systems that utilize liquid nitrogen to destroy tumors by freezing. Their minimally invasive technology serves as an alternative to surgical tumor removal, with a focus on treating breast, kidney, bone, and lung cancers. The company’s flagship product, the ProSense® system, is available globally for approved indications.

Average Trading Volume: 238,295

Technical Sentiment Signal: Strong Sell

Current Market Cap: $52.05M

See more insights into ICCM stock on TipRanks’ Stock Analysis page.